Molecular imaging markers in clinical trials in Alzheimer's disease

被引：7
|
作者：
Nordberg, A. [1 ]
机构：
[1] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Alzheimer Neurobiol, Dept NVS, Stockholm, Sweden
来源：
JOURNAL OF NUTRITION HEALTH & AGING | 2009年 / 13卷 / 04期
关键词：
Mild Cognitive Impairment; Rivastigmine; Mild Cognitive Impairment Patient; Cerebral Glucose Metabolism; Nicotine Binding;
D O I：
10.1007/s12603-009-0038-5
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
[No abstract available]
引用
收藏
页码：346 / 347
页数：2
相关论文
共 50 条
  • [1] Molecular imaging markers in clinical trials in Alzheimer’s disease
    A. Nordberg
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 346 - 347
  • [2] Biochemical markers in Alzheimer's disease clinical trials
    Zetterberg, Henrik
    Mattsson, Niklas
    Shaw, Les M.
    Blennow, Kaj
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 91 - 98
  • [3] Structural imaging markers for therapeutic trials in Alzheimer's disease
    Fox, N. C.
    Kennedy, J.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (04): : 350 - 352
  • [4] Structural imaging markers for therapeutic trials in Alzheimer’s disease
    N. C. Fox
    J. Kennedy
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 350 - 352
  • [5] Imaging endpoints for clinical trials in Alzheimer's disease
    Cash D.M.
    Rohrer J.D.
    Ryan N.S.
    Ourselin S.
    Fox N.C.
    Alzheimer's Research & Therapy, 6 (9)
  • [6] Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials
    Brosch, Jared R.
    Farlow, Martin R.
    Risacher, Shannon L.
    Apostolova, Liana G.
    NEUROTHERAPEUTICS, 2017, 14 (01) : 62 - 68
  • [7] Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials
    Jared R. Brosch
    Martin R. Farlow
    Shannon L. Risacher
    Liana G. Apostolova
    Neurotherapeutics, 2017, 14 : 62 - 68
  • [8] Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease
    Scheinin, Noora M.
    Scheinin, Mika
    Rinne, J. O.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 55 (03): : 265 - 279
  • [9] Biological and imaging markers as outcome measures for secondary prevention trials in Alzheimer's disease
    Hampel, H.
    EUROPEAN PSYCHIATRY, 2008, 23 : S39 - S40
  • [10] Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease
    Herholz, Karl
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 431 - 439
12345